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Stella M. Davies, Co-Editor, MBBS, PhD, John E. Levine, Co-Editor, MD, MSOne of themain goals of the annual TandemBlood
and Marrow Transplantation meeting is to provide an
outstanding educational experience for the attendees.
Each year the Program Committee selects topics and
speakers designed to sharpen our thinking about the
major issues in our field, so that we can return to our
respective centers energized to better help our patients
overcome the challenges they face. This year’s
program addresses some topics that have never been
previously addressed at a Tandem meeting, while up-
dating the status of some thorny problems that
continue to consume considerable attention. The
2012 Education Supplement on Hematopoietic Cell Trans-
plantation is provided as a resource for attendees to
complement the presentations at the meeting.
Among the topics covered in this year’s supplement
are new insights into the clinical relevance of natural
killer cells, next-generation sequencing, the interleukin-
17 pathway, tolerance, and graft-versus-host disease
(GVHD) biomarkers. Considerations for transplanta-
tion in the elderly patient, a rapidly increasing hemato-
poietic cell transplant population, are reviewed. The
evidence behind donor selection when only mismatched
unrelated,haploidentical related,orunrelated cordblood
sources are available is discussed in detail. Posttransplan-
tation complications that are major concerns for patients
and caregivers alike, such as chronicGVHD, secondma-
lignancies, cognitive functioning, and poor stamina, areerican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.11.019updated with the latest information on biology and ther-
apeutic interventions. New information relevant to the
treatment of patients with myeloma, leukemia, lym-
phoma, neuroblastoma, and nonmalignant disorders
are discussed. The data to support an emerging applica-
tion, transplantation for the treatment ofmultiple sclero-
sis, is summarized as is the approach to patients who have
HIV infection. An excellent point–counterpoint debate
over the use of anti-T cell antibodies is presented, along
with a summary of newer therapies for GVHD. Last
year’s nuclear accident in Japan highlights the timeliness
of an update of the role of the transplant team in the case
of radiation disasters. Last, and highly relevant to our
field, the optimal approach to clinical trial design for
rare diseases is presented.
Taken together, this supplement represents a com-
prehensive overview of some of the most important
issues in the field of hematopoietic cell transplantation
today. The opportunity to provide this supplement to
the readers is due to the dedication and willingness of
the authors to complete yet one more task in their busy
lives. On behalf of the American Society for Blood and
MarrowTransplantation and the Center for Blood and
MarrowTransplant Research, the editors would like to
thank all the authors for their excellent articles. We
also would like to thank the associate editors for their
careful reviews and, importantly, their adherence to
the necessary timeline.S1
